Hims & Hers Health, Inc. $HIMS Shares Acquired by Kornitzer Capital Management Inc. KS

Kornitzer Capital Management Inc. KS boosted its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 23.2% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 142,740 shares of the company’s stock after buying an additional 26,885 shares during the quarter. Kornitzer Capital Management Inc. KS owned approximately 0.06% of Hims & Hers Health worth $4,252,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in the company. Pictet Asset Management Holding SA lifted its stake in shares of Hims & Hers Health by 4.6% in the 3rd quarter. Pictet Asset Management Holding SA now owns 30,530 shares of the company’s stock valued at $909,000 after purchasing an additional 1,346 shares during the last quarter. Kestra Advisory Services LLC grew its position in shares of Hims & Hers Health by 22.3% in the third quarter. Kestra Advisory Services LLC now owns 20,900 shares of the company’s stock valued at $623,000 after purchasing an additional 3,811 shares during the last quarter. Greenfield Seitz Capital Management LLC increased its position in Hims & Hers Health by 4.6% in the 3rd quarter. Greenfield Seitz Capital Management LLC now owns 385,366 shares of the company’s stock worth $11,480,000 after buying an additional 17,027 shares during the period. Kurv Investment Management LLC raised its stake in Hims & Hers Health by 25.9% during the 3rd quarter. Kurv Investment Management LLC now owns 65,274 shares of the company’s stock valued at $1,945,000 after purchasing an additional 13,409 shares during the last quarter. Finally, Prosperitas Financial LLC acquired a new stake in Hims & Hers Health during the third quarter worth about $2,649,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Under the agreement, eligible patients with prescriptions from Hims & Hers’ licensed providers can access FDA-approved Zepbound and Foundayo at Lilly’s self-pay prices without leaving the platform. The deal broadens Hims & Hers’ weight-loss offering and may help it attract patients seeking branded obesity medicines. Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
• Positive Sentiment: Coverage of the collaboration described it as a catalyst for the stock, suggesting investors see the Lilly relationship as an important way to strengthen Hims & Hers’ position in the competitive weight-loss market. Why Hims & Hers Health Stock Was in Dire Need of This Eli Lilly Agreement
• Neutral Sentiment: Investors are also looking ahead to Hims & Hers’ Q3 results. A preview cited weight-loss demand, international expansion and subscriber growth as potential revenue drivers, with margins remaining an area to watch. HIMS’ Q3 Earnings: Can Weight Loss Momentum Drive Performance?

Hims & Hers Health Price Performance

Shares of HIMS opened at $25.95 on Monday. The firm has a market capitalization of $6.05 billion, a PE ratio of -41.19 and a beta of 2.53. Hims & Hers Health, Inc. has a 52-week low of $13.74 and a 52-week high of $42.70. The company has a debt-to-equity ratio of 4.21, a quick ratio of 0.87 and a current ratio of 0.93. The stock has a 50 day simple moving average of $28.43 and a 200 day simple moving average of $26.94.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.32). Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%. The company had revenue of $753.21 million for the quarter, compared to the consensus estimate of $698.90 million. During the same period in the prior year, the company earned $0.17 EPS. The firm’s revenue was up 38.2% on a year-over-year basis. Sell-side analysts predict that Hims & Hers Health, Inc. will post -0.16 EPS for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other news, CFO Oluyemi Okupe sold 29,277 shares of the firm’s stock in a transaction that occurred on Tuesday, September 22nd. The shares were sold at an average price of $29.95, for a total transaction of $876,846.15. Following the completion of the transaction, the chief financial officer directly owned 236,527 shares of the company’s stock, valued at $7,083,983.65. This trade represents a 11.01% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Soleil Boughton sold 25,111 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $27.55, for a total transaction of $691,808.05. Following the transaction, the insider directly owned 313,964 shares of the company’s stock, valued at $8,649,708.20. This represents a 7.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 133,905 shares of company stock worth $3,826,977. Insiders own 11.76% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Needham & Company LLC boosted their price target on shares of Hims & Hers Health from $35.00 to $42.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Barclays reduced their price objective on Hims & Hers Health from $39.00 to $35.00 and set an “overweight” rating on the stock in a research note on Friday, August 21st. Wall Street Zen upgraded Hims & Hers Health from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Deutsche Bank Aktiengesellschaft raised their target price on Hims & Hers Health from $25.00 to $26.00 and gave the company a “hold” rating in a research note on Tuesday, August 11th. Finally, TD Cowen lifted their price target on Hims & Hers Health from $25.00 to $30.00 and gave the company a “hold” rating in a report on Tuesday, August 11th. Three analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Hims & Hers Health presently has an average rating of “Hold” and a consensus price target of $32.43.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a consumer-focused telehealth platform that connects patients with licensed healthcare providers and offers access to treatments and wellness products. Its services include online consultations, prescription care and over-the-counter products.

The company serves a range of health needs, including hair loss, sexual health, skin care, mental health and weight management. Its platform also offers primary care and other services, with offerings varying by location and individual eligibility.

Founded in 2017, the company initially launched its Hims brand and later introduced Hers, expanding its services to a broader audience.